Shima Kenji, Komatsu Machiko, Noma Yoshihiko, Miya Keiko
Department of Diabetes and Medicine, Kawashima Hospital, Japan.
Intern Med. 2014;53(8):829-35. doi: 10.2169/internalmedicine.53.1364. Epub 2014 Apr 15.
The aim of this study was to compare the utility of hemoglobin A1c (HbA1c) and glycated albumin (GA) for evaluating the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, in patients with type 2 diabetes.
Sitagliptin (50 mg) was administered orally once daily in 67 outpatients with type 2 diabetes. Drug effectiveness was deemed present if the HbA1c or GA level decreased by 5% at week 4 and week 12 relative to the baseline value.
The mean HbA1c level decreased from 8.1 ± 1.0% at baseline to 7.8 ± 0.9% at week 4 and 7.2 ± 0.8% at week 12. The mean GA level decreased from 25.0 ± 4.5% at baseline to 22.2 ± 3.8% at week 4 and 20.8 ± 3.5% at week 12. At week 4 and week 12, the drug was effective in 37.8% and 71.6% of the patients, respectively, when assessed based on changes in HbA1c, and in 83.6% and 97.0% of the patients, respectively, when assessed based on changes in GA.
GA is superior to HbA1c for evaluating the efficacy of sitagliptin treatment in patients with type 2 diabetes.
本研究旨在比较糖化血红蛋白（HbA1c）和糖化白蛋白（GA）在评估2型糖尿病患者中使用二肽基肽酶-4（DPP-4）抑制剂西他列汀疗效方面的效用。
67例2型糖尿病门诊患者每日口服一次西他列汀（50毫克）。如果在第4周和第12周时HbA1c或GA水平相对于基线值下降5%，则认为药物有效。
平均HbA1c水平从基线时的8.1±1.0%降至第4周时的7.8±0.9%和第12周时的7.2±0.8%。平均GA水平从基线时的25.0±4.5%降至第4周时的22.2±3.8%和第12周时的20.8±3.5%。在第4周和第12周时，基于HbA1c变化评估，药物分别在37.8%和71.6%的患者中有效；基于GA变化评估，药物分别在83.6%和97.0%的患者中有效。
在评估西他列汀治疗2型糖尿病患者的疗效方面，GA优于HbA1c。
